LONDON-- The European Medicines Agency Friday confirmed a risk of slow heart rate or problems with conduction of electrical signals in the heart when the hepatitis C medicines Harvoni, produced by Gilead Sciences Inc. (GILD), or a combination of Gilead's Sovaldi and Bristol-Myers Squibb Co's (BMY) Daklinza are used in patients who are also taking the medicine amiodarone.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gilead Sciences Charts.